Tryvio (aprocitentan) now included in ACC/AHA clinical practice guidelines for the treatment of hypertension – Idorsia
Idorsia Ltd announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic hypertension, published by the American College of Cardiology (ACC) and the American Heart Association (AHA) Joint Committee. The updated recommendations now list Tryvio as a therapy that may be added for adults with difficult-to-control hypertension, including resistant hypertension. Tryvio is the first systemic hypertension treatment to target a new pathway in over 30 years and the only new medicine to be included in the updated guidelines.
The new guidelines will be discussed at the upcoming American Heart Association’s (AHA) Hypertension Scientific Sessions held September 4-7 in Baltimore, MD. In addition, Idorsia will present two scientific posters at the congress. One poster presents post-hoc analysis demonstrating that aprocitentan provided fast blood pressure control and a substantial UACR reduction which were both sustained until Week 36 in patients with grade 2 hypertension (defined as systolic blood pressure 160 to 179 mmHg) at baseline. The other poster presents post-hoc analysis in patients with isolated systolic hypertension-like characteristics at baseline, showing that aprocitentan substantially reduced systolic blood pressure while maintaining diastolic blood pressure above 70 mmHg to achieve clinically optimal values associated with minimal cardiovascular risk.
Dr. Srishti Gupta, Chief Executive Officer of Idorsia, commented: “Idorsia is grateful to the medical community and the joint guidelines committee for recognizing TRYVIO as an important option for patients with difficult-to-control hypertension. The clinical evidence from the development program has demonstrated that targeting the endothelin pathway in hypertension with TRYVIO can help address a critical unmet medical need. The TRYVIO approval and inclusion in the updated clinical practice guidelines are a testament to our commitment to discover and develop innovative medicines that improve patient outcomes.”
